GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Loans Receivable

Abbisko Cayman (HKSE:02256) Loans Receivable : HK$0.0 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Loans Receivable?

Abbisko Cayman's Loans Receivable for the quarter that ended in Jun. 2024 was HK$0.0 Mil.


Abbisko Cayman Loans Receivable Historical Data

The historical data trend for Abbisko Cayman's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Loans Receivable Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial - - - - -

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abbisko Cayman Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Abbisko Cayman Loans Receivable Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbisko Cayman Business Description

Traded in Other Exchanges
Address
Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.
Executives
Xu Yao-chang 2101 Beneficial owner
Qiming Corporate Gp Vi, Ltd. 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Chen Zhui 2501 Other
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Shi Yi 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Futu Trustee Limited 2301 Trustee
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Morgan Stanley 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Computershare Hong Kong Trustees Limited 2301 Trustee
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you

Abbisko Cayman Headlines

No Headlines